VTRS

Viatris Inc

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001792044
$16.48 +1.04% $19.2B
High Impact Filing (7/10)35 New Institutional Positions15 Institutional Exits
Vol
Market Cap$19.2B
Cap SizeLarge Cap
Analyst ConsensusBuy (67%)
Inst. Holders50 funds
Inst. Value$8.8B
Inst. Activity35 buys / 15 sells
Insider Activity0B / 1S
Insider Net $-$283.5K
SEC Reports4
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001792044·Prev Close $16.31

Recent Activity

May 13, 2026 SEC
The Federal Circuit affirmed the district court's ruling that Mylan Pharmaceuticals does not infringe Actelion's patents
COURT-RULING — Impact 7/10
May 7, 2026 SEC
Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus
8-K — Impact 7/10
May 4, 2026 SEC
Viatris CFO Theodora Mistras voluntarily departs for another opportunity; CAO Paul Campbell appointed interim CFO effect
8-K — Impact 3/10
Apr 15, 2026 Insider
Le Goff Corinne acquired via exercise 39,344 shares
Chief Commercial Officer
Apr 15, 2026 Insider
Le Goff Corinne surrendered for taxes 17,450 shares
Chief Commercial Officer @ $13.86 ($241.9K)
Apr 15, 2026 Insider
Le Goff Corinne acquired via exercise 3,643.834 shares
Chief Commercial Officer
Inst.
Rubric Capital Management LP — ADD
33,500,000 shares ($452.6M)
Inst.
AMERIPRISE FINANCIAL INC — TRIM
20,014,966 shares ($270.4M)

Price Targets

$17.81 +8.1% upside Buy
Current $16.48 Low $12.00 Median $17.50 High $23.00 8 analysts
$12.00 $23.00

Analyst Ratings

Buy67% buy · 18 analysts
4Strong Buy
8Buy
5Hold
1Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 19, 2026 Barclays MAINTAIN Overweight → Overweight
May 8, 2026 JP Morgan MAINTAIN Neutral → Neutral
May 8, 2026 Truist Securities MAINTAIN Buy → Buy
Mar 24, 2026 Barclays MAINTAIN Overweight → Overweight
Jan 28, 2026 Piper Sandler MAINTAIN Neutral → Neutral

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.60 ▼ -0.9% $0.57 — $0.63 -3% YoY 8
Next Q $0.65 $0.61 — $0.69 -4% YoY 8
Current FY $2.46 $2.38 — $2.60 5% YoY 9
Next FY $2.66 $2.46 — $2.99 8% YoY 9

Latest Reports

BULLISH COURT-RULING 7/10
The Federal Circuit affirmed the district court's ruling that Mylan Pharmaceuticals does not infringe Actelion's patents
May 13, 2026
BULLISH 8-K 7/10
Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus
May 7, 2026

Top Institutional Holders

FundValueMove
BlackRock, Inc.$1.1B—
DAVIS SELECTED ADVISERS$1.1B—
VANGUARD CAPITAL MANAGEMENT LLC$1.0B—
VANGUARD PORTFOLIO MANAGEMENT LLC$728.3M—
STATE STREET CORP$705.7M—

Recent Insider Trades

DateInsiderTypeValue
Apr 15, 2026Le GoffM$0.00
Apr 15, 2026Le GoffF$241.9K
Apr 15, 2026Le GoffM$0.00
Mar 23, 2026Campbell PaulSELL$283.5K
Mar 6, 2026FINNEY ELISHAM$0.00
50 institutional holders with $8.8B total value (652,049,471 shares) as of 2026-Q1. Top holders: BlackRock,, DAVIS, VANGUARD. Net buying activity: 35 institutions added/increased vs 15 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BlackRock, Inc.84,359,804$1.1B12.9%—
2DAVIS SELECTED ADVISERS78,211,191$1.1B12.0%—
3VANGUARD CAPITAL MANAGEMENT LLC74,716,631$1.0B11.5%—
4VANGUARD PORTFOLIO MANAGEMENT LLC53,911,237$728.3M8.3%—
5STATE STREET CORP52,233,699$705.7M8.0%—
6DIMENSIONAL FUND ADVISORS LP38,310,693$517.5M5.9%—
7Rubric Capital Management LP33,500,000$452.6M5.1%ADD +31.4%
8Invesco Ltd.21,968,657$296.8M3.4%—
9AMERIPRISE FINANCIAL INC20,014,966$270.4M3.1%TRIM -25.4%
10FMR LLC16,588,514$224.1M2.5%—
11MORGAN STANLEY16,089,939$217.4M2.5%—
12GOLDMAN SACHS GROUP INC13,717,622$185.3M2.1%—
13CHARLES SCHWAB INVESTMENT MANAGEMENT INC13,674,306$184.7M2.1%—
14MARSHALL WACE, LLP9,349,817$126.3M1.4%DOUBLED +2220.9%
15ARROWSTREET CAPITAL, LIMITED PARTNERSHIP8,545,196$115.4M1.3%—
16Pacer Advisors, Inc.8,033,876$108.5M1.2%DOUBLED +8694.2%
17BANK OF AMERICA CORP /DE/7,259,555$98.1M1.1%—
18DEUTSCHE BANK AG\6,512,440$88.0M1.0%ADD +52.8%
19VANGUARD FIDUCIARY TRUST CO6,485,909$87.6M1.0%—
20JUPITER ASSET MANAGEMENT LTD5,768,153$77.9M0.9%ADD +47.5%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
Rubric Capital Management LPADD25,500,00033,500,000+31.4%$452.6M2026-Q1
AMERIPRISE FINANCIAL INCTRIM26,845,38920,014,966-25.4%$270.4M2026-Q1
MARSHALL WACE, LLPDOUBLED402,8599,349,817+2220.9%$126.3M2026-Q1
Pacer Advisors, Inc.DOUBLED91,3548,033,876+8694.2%$108.5M2026-Q1
DEUTSCHE BANK AG\ADD4,262,8856,512,440+52.8%$88.0M2026-Q1
JUPITER ASSET MANAGEMENT LTDADD3,909,3045,768,153+47.5%$77.9M2026-Q1
FRANKLIN RESOURCES INCDOUBLED908,6845,569,529+512.9%$75.2M2026-Q1
Gotham Asset Management, LLCADD3,545,1104,500,352+26.9%$60.8M2026-Q1
SEI INVESTMENTS COADD2,788,7333,720,915+33.4%$50.3M2026-Q1
AmundiADD1,828,9063,407,023+86.3%$46.0M2026-Q1
VICTORY CAPITAL MANAGEMENT INCTRIM3,399,1772,394,145-29.6%$32.3M2026-Q1
CAPITOLIS LIQUID GLOBAL MARKETS LLCADD1,018,0001,901,000+86.7%$25.7M2026-Q1
Point72 Asset Management, L.P.NEW—1,777,181—$24.0M2026-Q1
BNP Paribas Asset Management Holding S.A.TRIM1,559,3641,108,006-28.9%$15.0M2026-Q1
Trexquant Investment LPDOUBLED218,605882,688+303.8%$11.9M2026-Q1
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW—833,436—$11.3M2026-Q1
Assenagon Asset Management S.A.NEAR_EXIT3,574,684783,134-78.1%$10.6M2026-Q1
NATIONAL BANK OF CANADA /FI/ADD483,752754,655+56.0%$10.2M2026-Q1
Universal- Beteiligungs- und Servicegesellschaft mbHADD458,908649,903+41.6%$8.8M2026-Q1
Brevan Howard Capital Management LPDOUBLED104,237433,509+315.9%$5.9M2026-Q1
FIFTH THIRD BANCORPDOUBLED99,873422,971+323.5%$5.7M2026-Q1
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.DOUBLED120,653391,326+224.3%$5.3M2026-Q1
TD ASSET MANAGEMENT INCADD203,876369,546+81.3%$5.0M2026-Q1
Vident Advisory, LLCDOUBLED160,846350,648+118.0%$4.7M2026-Q1
TORONTO DOMINION BANKNEAR_EXIT2,824,051344,036-87.8%$4.6M2026-Q1
14 unique insiders with 50 transactions. Net insider value: -$283.5K ($0.00 bought, $283.5K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Apr 15, 2026Le Goff CorinneChief Commercial OfficerEXERCISE39,344——
Apr 15, 2026Le Goff CorinneChief Commercial OfficerTAX W/H17,450$13.86$241.9K
Apr 15, 2026Le Goff CorinneChief Commercial OfficerEXERCISE3,643.834——
Mar 23, 2026Campbell PaulSee RemarksSELL21,350$13.28$283.5K
Mar 6, 2026FINNEY ELISHA WDirectorEXERCISE23,660——
Mar 6, 2026FINNEY ELISHA WDirectorEXERCISE1,174.492——
Mar 6, 2026FINNEY ELISHA WDirectorAWARD15,890——
Mar 6, 2026Campbell PaulSee RemarksEXERCISE27,603——
Mar 6, 2026Campbell PaulSee RemarksTAX W/H12,088$14.16$171.2K
Mar 6, 2026Campbell PaulSee RemarksEXERCISE1,370.623——
Mar 6, 2026Campbell PaulSee RemarksAWARD56,727——
Mar 6, 2026Smith Scott AndrewChief Executive OfficerEXERCISE124,519——
Mar 6, 2026Smith Scott AndrewChief Executive OfficerTAX W/H48,999$14.16$693.8K
Mar 6, 2026Smith Scott AndrewChief Executive OfficerEXERCISE6,181.424——
Mar 6, 2026Smith Scott AndrewChief Executive OfficerAWARD256,074——
Mar 6, 2026Maletta Matthew JosephChief Legal OfficerAWARD59,323——
Mar 6, 2026HIGGINS MELINA EDirectorEXERCISE23,660——
Mar 6, 2026HIGGINS MELINA EDirectorEXERCISE1,174.492——
Mar 6, 2026HIGGINS MELINA EDirectorAWARD15,890——
Mar 6, 2026KILTS JAMES MDirectorEXERCISE23,660——
Mar 6, 2026KILTS JAMES MDirectorEXERCISE1,174.492——
Mar 6, 2026KILTS JAMES MDirectorAWARD15,890——
Mar 6, 2026Enrietti AndrewSee RemarksEXERCISE19,169——
Mar 6, 2026Enrietti AndrewSee RemarksTAX W/H8,337$14.16$118.1K
Mar 6, 2026Enrietti AndrewSee RemarksEXERCISE19,169——
Mar 6, 2026Enrietti AndrewSee RemarksEXERCISE951.622——
Mar 6, 2026Enrietti AndrewSee RemarksAWARD60,435——
Mar 6, 2026SIMMONS DAVID SDirectorEXERCISE22,820——
Mar 6, 2026SIMMONS DAVID SDirectorEXERCISE523.04——
Mar 6, 2026SIMMONS DAVID SDirectorAWARD15,890——
Mar 6, 2026DAMELIO FRANK ADirectorEXERCISE25,112——
Mar 6, 2026DAMELIO FRANK ADirectorEXERCISE918.455——
Mar 6, 2026DAMELIO FRANK ADirectorAWARD15,890——
Mar 6, 2026MARK RICHARD ADirectorEXERCISE23,660——
Mar 6, 2026MARK RICHARD ADirectorEXERCISE1,174.492——
Mar 6, 2026MARK RICHARD ADirectorAWARD15,890——
Mar 6, 2026Le Goff CorinneChief Commercial OfficerEXERCISE44,165——
Mar 6, 2026Le Goff CorinneChief Commercial OfficerTAX W/H19,588$14.16$277.4K
Mar 6, 2026Le Goff CorinneChief Commercial OfficerEXERCISE2,192.007——
Mar 6, 2026Le Goff CorinneChief Commercial OfficerAWARD88,984——
Mar 6, 2026Mistras TheodoraChief Financial OfficerEXERCISE41,711——
Mar 6, 2026Mistras TheodoraChief Financial OfficerTAX W/H23,067$14.16$326.6K
Mar 6, 2026Mistras TheodoraChief Financial OfficerEXERCISE2,070.604——
Mar 6, 2026Mistras TheodoraChief Financial OfficerAWARD86,017——
Mar 6, 2026SEVERINO MICHAELDirectorEXERCISE25,112——
Mar 6, 2026SEVERINO MICHAELDirectorEXERCISE918.455——
Mar 6, 2026SEVERINO MICHAELDirectorAWARD15,890——
Mar 6, 2026PARRISH MARK WDirectorEXERCISE23,660——
Mar 6, 2026PARRISH MARK WDirectorEXERCISE1,174.492——
Mar 6, 2026PARRISH MARK WDirectorAWARD15,890——
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 6.0/10.
BULLISH COURT-RULING 7/10
The Federal Circuit affirmed the district court's ruling that Mylan Pharmaceuticals does not infring
May 13, 2026
BULLISH 8-K 7/10
Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B,
May 7, 2026
NEUTRAL 8-K 3/10
Viatris CFO Theodora Mistras voluntarily departs for another opportunity; CAO Paul Campbell appointe
May 4, 2026
MIXED 8-K 7/10
Viatris reported mixed financial results for 2025, with full-year revenue declining 3% YoY but fourt
Feb 26, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Buy (67% buy). Based on 18 analysts: 4 strong buy, 8 buy, 5 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$17.81 mean target +8.1% upside Buy (2.20)
$12.00 Low $23.00 High
MetricValue
Current Price$16.48
Target Low$12.00
Target Mean$17.81
Target Median$17.50
Target High$23.00
# Analysts8
RecommendationBuy (2.20)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.60 $0.57 $0.63 -2.6% -0.9% 3↑ 3↓ $3.7B 2.2% 8
Next Q
2026-09-30
 $0.65 $0.61 $0.69 -3.7% -0.4% 0↑ 7↓ $3.8B 1.8% 8
Current FY
2026-12-31
 $2.46 $2.38 $2.60 4.9% +0.3% 5↑ 3↓ $14.8B 3.3% 9
Next FY
2027-12-31
 $2.66 $2.46 $2.99 8.1% -0.5% 3↑ 5↓ $15.0B 1.8% 9

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.604
7d ago$0.605-0.001
30d ago$0.610-0.006
60d ago$0.611-0.007
90d ago$0.606-0.002
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 19, 2026 Barclays MAINTAIN Overweight Overweight
May 8, 2026 JP Morgan MAINTAIN Neutral Neutral
May 8, 2026 Truist Securities MAINTAIN Buy Buy
Mar 24, 2026 Barclays MAINTAIN Overweight Overweight
Jan 28, 2026 Piper Sandler MAINTAIN Neutral Neutral
Jan 16, 2026 Argus Research UPGRADE Hold Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264851067%
May 1, 20264851067%
Apr 1, 20264851067%
Mar 1, 20264851067%
Feb 1, 20264752061%
Jan 1, 20263762056%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Oct 17, 2026
fda_pdufa
PDUFA: VTRS — MR-141 in presbyopia — 2026-10-17
FDA target action date 2026-10-17 for VTRS (Viatris Inc). Drug: MR-141. Indication: presbyopia. PDUFA goal date for MR-141 (phentolamine ophthalmic so
Jul 30, 2026
fda_pdufa
PDUFA: VTRS — low-dose estrogen weekly patch in contraception — 2026-07-30
FDA target action date 2026-07-30 for VTRS (Viatris Inc). Drug: low-dose estrogen weekly patch. Indication: contraception. PDUFA goal date for investi
Jun 11, 2026
Clinical Trial
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Phase Phase 2 — COMPLETED
Jun 10, 2026
Clinical Trial
Combining Varenicline and Guanfacine for Smoking Cessation
Phase Phase 2 — COMPLETED
Jun 10, 2026
short_volume
Short Volume: VTRS — 59.3% short (1.3M / 2.2M)
Short: 1,307,843 | Exempt: 358 | TRF Vol: 2,207,046 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: VTRS — 61.1% short (1.5M / 2.5M)
Short: 1,520,066 | Exempt: 3,989 | TRF Vol: 2,486,996 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: VTRS — 60.0% short (1.5M / 2.4M)
Short: 1,455,017 | Exempt: 297 | TRF Vol: 2,425,914 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
Clinical Trial
Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis
Phase Phase 3 — TERMINATED
Jun 4, 2026
Clinical Trial
Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia
Phase Phase 2 — TERMINATED
Jun 4, 2026
FDA
Liothyronine Sodium
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS • Thyroid hormones, including LIOTHYRONINE SODIUM, either alone or with other therapeutic age
Jun 3, 2026
Clinical Trial
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
Phase Phase 2 — COMPLETED
May 23, 2026
FDA
misoprostol
WARNINGS MISOPROSTOL ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE BIRTH DEFECTS, ABORTION, PREMATURE BIRTH OR UTERINE RUPTURE. UTERINE RUPTURE H
May 22, 2026
FDA
Diclofenac sodium and Misoprostol
WARNING: RISK OF UTERINE RUPTURE, ABORTION, PREMATURE BIRTH, BIRTH DEFECTS; SERIOUS CARDIOVASCULAR EVENTS; AND SERIOUS GASTROINTESTINAL EVENTS Uterine
May 20, 2026
short_volume
Short Volume: VTRS — 59.5% short (2.1M / 3.6M)
Short: 2,129,526 | Exempt: 526 | TRF Vol: 3,576,073 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: VTRS — 64.0% short (3.2M / 5.1M)
Short: 3,246,859 | Exempt: 161,596 | TRF Vol: 5,076,304 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: VTRS — 9.8M shares, 92,898 trades
Week starting 2026-05-18. Total ATS volume: 9,843,112 shares across 92,898 trades.
May 14, 2026
short_volume
Short Volume: VTRS — 55.8% short (2.0M / 3.6M)
Short: 2,008,690 | Exempt: 2,649 | TRF Vol: 3,599,234 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: VTRS — 65.7% short (2.4M / 3.7M)
Short: 2,430,678 | Exempt: 12,230 | TRF Vol: 3,697,673 | Short Ratio: 65.7% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: VTRS — 14.0M shares, 109,373 trades
Week starting 2026-05-11. Total ATS volume: 13,974,462 shares across 109,373 trades.
May 8, 2026
short_interest
FTD: VTRS — 41,581 shares ($0.7M) failed to deliver
Settlement: 20260508, Price: $17.39, FTD Value: $723,093.59, VIATRIS INC COM
May 7, 2026
earnings_calendar
VTRS Q1 2026 Earnings Scheduled — 2026-05-07
May 7, 2026
short_interest
FTD: VTRS — 49,775 shares ($0.8M) failed to deliver
Settlement: 20260507, Price: $15.95, FTD Value: $793,911.25, VIATRIS INC COM
May 5, 2026
short_volume
Short Volume: VTRS — 59.2% short (4.3M / 7.3M)
Short: 4,329,832 | Exempt: 6,533 | TRF Vol: 7,319,084 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 3, 2026
FDA
Liothyronine Sodium
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS • Thyroid hormones, including LIOTHYRONINE SODIUM, either alone or with other therapeutic age
Apr 28, 2026
FDA
clindamycin hydrochloride
WARNING Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin HCl